Amitkumar Mehta, MD, UAB School of Medicine, Birmingham, AL, discusses data from the dose-escalation, Phase I CC-95251-ST-001 trial (NCT03783403) of CC-95251, an anti-signal regulatory protein-alpha (SIRPα) antibody, in patients with CD20+ relapsed/refractory non-Hodgkin lymphoma (NHL). Patients predominantly with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma (MCL) received 3, 10, or 20 mg/kg of CC-95251 with rituximab, and reported encouraging efficacy with an acceptable safety profile. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

свернуть